Fear to greed in 14 days flat.

That’s what we just witnessed in this market.

While everyone’s been busy piling back into tech and AI darlings, they’re completely missing what’s happening in biotech.

Specifically, they’re sleeping on Amgen (AMGN).

Look, I’ve been tracking this setup for a while, and it’s getting too juicy to ignore.

While the market’s attention is elsewhere, Amgen is sitting 22% below its March highs – creating one of those rare asymmetric opportunities that doesn’t come around often.

What’s crazy is that nothing fundamentally changed with the company.

They still have: • A rock-solid diversified portfolio (no single drug makes up more than 15% of revenue) • Consistent free cash flow that would make most companies jealous • A potential blockbuster in the $100 billion weight-loss market that nobody’s talking about

When I see setups like this – quality companies getting unfairly punished while the market chases shiny objects – my opportunity radar starts beeping like crazy.

Let me break down exactly why this pullback is a gift, not a warning sign, and why Amgen deserves a spot on your watchlist right now.

Diversification = Stability = Opportunity

Amgen has 42 medicines on the market, and guess what? Not a single one represents more than 15% of their total revenue.

I know what you’re thinking: “Wait, Bryan, is that a good thing or a bad thing?” Well, it’s both.

Here’s the downside: when you’re that diversified, it’s harder for one blockbuster drug to move the needle.

But here’s the upside: Amgen is rock solid. Unlike some smaller biotech companies that live or die by one or two drugs, Amgen’s revenue is consistent and dependable.

Even if one drug faces biosimilar competition or loses patent protection, they’ve got 41 others to pick up the slack.

That’s why Amgen keeps generating strong free cash flow—and that’s what gives them the firepower to keep innovating.

GLP-1: The $100 Billion Weight-Loss Catalyst

Now, let’s talk about the opportunity everyone’s ignoring: weight loss.

The global obesity market is projected to hit $100 billion by 2030, and right now, GLP-1 inhibitors like Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) are leading the way.

But here’s the kicker: Amgen is coming for a piece of the pie with their weight-loss candidate, MariTide.

Here’s why MariTide could be a game-changer:

• It’s designed to be longer-lasting and more effective than existing options.
• Its once-monthly dosing makes it more convenient for patients, which could drive adoption.

Let me be clear: MariTide is still in Phase 2 and 3 trials, so it’s not a sure thing. But if Amgen can deliver—and even capture a small slice of the market—it could be a huge win for the stock.

What About the Pullbacks? Here’s Why They’re Bullish

I get it. Amgen’s stock hasn’t been the market’s darling lately.

And now it’s 22% off its recent highs. But here’s what most people don’t realize: pullbacks like this create opportunity.

Let’s break down what’s happening right now:

• The Horizon Acquisition: Sure, Amgen took on $57 billion in debt to acquire Horizon Therapeutics. But that deal brought in three new drugs, including Uplizna, which has real growth potential in the years ahead.
• Signs of Growth: In Q1 2025, Amgen’s product sales grew 11% year-over-year. That’s solid, steady growth—not the kind of thing that makes headlines, but exactly what you want from a company like this.
• Technical Setup: For the past decade, Amgen’s stock has traded in a predictable channel. And right now, it’s sitting near the bottom of that range, which gives long-term investors a great risk-reward setup.

Here’s the thing: the market might not love Amgen today, but that’s exactly why it’s interesting. With shares trading 22% off their highs, this pullback looks like a great place to step in.

But What About the Risks?

Let’s keep it real—no stock is risk-free, and Amgen has its challenges:

• Debt Load: Their $57 billion debt pile is massive, and deleveraging has been slow. High interest rates will only make this harder.
• Biosimilar Competition: Key drugs like Prolia and Xgeva are facing sales erosion as competitors enter the market.
• Weight Loss Uncertainty: MariTide is still in trials, and there’s no guarantee it will outperform Novo Nordisk and Eli Lilly.

But you know what?

This isn’t some speculative penny stock. Amgen has the cash flow, the pipeline, and the expertise to manage these risks while still delivering value to shareholders.

Your Action Plan

Amgen is a high-quality biotech stock with a diversified portfolio, strong cash flow, and massive upside in the weight-loss market.

Sure, the market likes to focus on short-term noise, but that’s exactly what gives you an edge.

Shares were trading in the 340s in late March, and is now $70 off from those levels.

Will you be the person who saw the opportunity, took action, and cashed in while everyone else was distracted.

This is just one of the many opportunities we uncover in Catalyst Cashouts Live.

If you’re ready to go deeper–breaking down the markets, identifying undervalued plays, and positioning for profits with real-time trade alerts–it's time to join Catalyst Cashouts Live today.

Don’t miss another opportunity like Amgen. These setups appear constantly, but only members get the alerts.

Click here to join Catalyst Cashouts Live now